Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US20110130301: Settings for recombinant adenoviral-based vaccines

Share

Filing Information

Inventor(s) Menzo J. E. Havenga · Stefan Kostense ·
Assignee(s) None listed in document.
Application Number US12930661
Filing date 01/12/2011
Publication date 06/02/2011
Predicted expiration date 10/23/2023
U.S. Classifications 506/9  · 435/5  ·
International Classifications C12Q170  · C40B3004  ·
Kind CodeA1
Foreign Priority NLPCTNL0200671 - 10/23/2002 ·
12 Claims, 37 Drawings


Abstract

Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Independent Claims | See all claims (12)

  1. 1.-38. (canceled)
  2. 39. A method for determining a titer of neutralizing antibodies directed against adenoviruses in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of the human or animal; culturing host cells which can be infected with a recombinant adenovirus; admixing the serum sample, the host cell culture and the recombinant adenovirus, wherein the recombinant adenovirus comprises a transgene encoding luciferase; incubating the admixture for about 24 hours; determining the activity of luciferase in the admixture; and comparing the activity of luciferase in the admixture to a serum-free control, thereby determining the titer of neutralizing antibodies in the blood sample; wherein the titer of neutralizing antibodies is determinable with 1000 host cells.
  3. 40. (canceled)
  4. 42. (canceled)
  5. 45.-53. (canceled)
  6. 56. A high-throughput method for determining a titer of neutralizing antibodies directed against adenoviruses in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of said human or animal; culturing host cells which can be infected with a recombinant adenovirus; admixing the serum sample, the host cell culture and recombinant adenovirus, wherein the recombinant adenovirus comprises a transgene encoding luciferase; incubating the admixture for about 24 hours; determining the activity of luciferase in the admixture; and comparing the activity of luciferase in the admixture to a serum-free control, thereby determining the titer of neutralizing antibodies in the serum sample; wherein 1000 host cells are sufficient to determine the titer of neutralizing antibodies.
  7. 57. A method for determining the relative titers of neutralizing antibodies directed against adenoviruses of different serotypes in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of said human or animal; providing cultured host cells which can be infected by recombinant adenovirus of a first serotype and a second serotype; admixing a first portion of the serum sample, a first portion of the cultured host cells and a recombinant adenovirus of the first serotype to form a first admixture, wherein the recombinant adenovirus of the first serotype comprises a transgene encoding luciferase; admixing a second portion of the serum sample, a second portion of the cultured host cells and a recombinant adenovirus of the second serotype to form a second admixture, wherein the recombinant adenovirus of the second serotype comprises a transgene encoding luciferase; incubating the admixtures for about 24 hours; determining the activity of luciferase in both the first and second admixtures; and comparing the luciferase activities in the first and second admixtures to a serum-free control, thereby determining the relative titers of neutralizing antibodies to adenoviruses of the first and second serotypes in the serum sample; wherein 1000 host cells will provide a titer of neutralizing antibodies.

References Cited

The current document has no citations.

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.